Revlimid: Medgend

Revlimid FDA Approved Drugs

REVLIMID [Lenalidomide^{C₁₃H₁₃N₃O₃}]

10mg (oral capsule)

15mg (oral capsule)

2.5mg (oral capsule)

20mg (oral capsule)

25mg (oral capsule)

Celgene^{Dec 27, 2005}

Treatment of male patient having a disease or condition responsive to a teratogenic drug.
Use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma.
Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha.
Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide).

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.